Advertisement
Shree Cement, one of India’s top cement manufacturers, is running its oxygen plants at 100% capacity to cater to the shortage of oxygen in the country. Shree Cement has already supplied over 12 500 oxygen cylinders and is continuing to supply to the hospitals across India from its production units in Rajasthan, Karnataka, Bihar, Odisha and Chhattisgarh. The plants are also providing free oxygen refills at all its units.
While India’s massive vaccination programme against Covid-19 to restore normalcy is currently on, the country has been hit by a second wave of more transmissible mutant variants of the Covid virus causing a sudden spike in the numbers of those affected. This has led to a shortage of oxygen in the hospitals.
Sparta family launches toy drive as anniversary of son s death approaches
fox17online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fox17online.com Daily Mail and Mail on Sunday newspapers.
Investegate |Sareum Holdings PLC Announcements | Sareum Holdings PLC: Half-year Report
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Patients with acute respiratory failure may now enroll in NIH-sponsored trial.
A CCL-81 cell (purple) infected with SARS-CoV-2 virus particles, which are the small spherical structures (teal). The string-like protrusions extending from the cell are cell projections or pseudopodium, whose primary purposes are cell mobility and ingestion of nutrients. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.NIAID
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure. The trial is supported by two components of the National Institutes of Health, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI), and is part of the NIH Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) public-private partnership.